Investment Thesis
SpyGlass Pharma exhibits severe financial distress with negative stockholders equity of -$98.8M, zero revenue generation, and operating losses that deteriorated 36.7% year-over-year to -$39.9M. At current cash burn of $33.5M annually, the company faces insolvency within 2-3 years without significant strategic intervention or additional capital.
Strengths
- Cash position of $96.4M provides near-term operational runway
- Low absolute debt burden at $10.2M total liabilities
- Strong liquidity ratios (12.67x current ratio) for working capital needs
Risks
- Negative stockholders equity of -$98.8M indicates technical insolvency and balance sheet distress
- Zero revenue despite being in medical device sector suggests pre-revenue stage or fundamental business model failure
- Accelerating losses: net income declined 36.7% YoY with operating cash flow negative $32.7M
- At $33.5M annual free cash burn, company has approximately 2.9 years of runway before liquidity crisis
- Deteriorating profitability across all metrics with no visible path to breakeven within forecast period
Key Metrics to Watch
- First revenue recognition and commercial launch milestones
- Quarterly cash burn rate trend and covenant to preserve runway
- FDA regulatory approvals or clinical trial milestones for medical devices
- Successful capital raise and dilution impact to equity structure
- Operating expense reduction initiatives and path to cash flow breakeven
Financial Metrics
Revenue
N/A
Net Income
-39.9M
EPS (Diluted)
$-17.98
Free Cash Flow
-33.5M
Total Assets
115.9M
Cash
96.4M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
N/A
ROA
-34.4%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
12.67x
Quick Ratio
12.67x
Debt/Equity
N/A
Debt/Assets
8.8%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-15T19:27:23.259970 |
Data as of: 2025-12-31 |
Powered by Claude AI